Artivion (NYSE:AORT) Coverage Initiated at JMP Securities

Stock analysts at JMP Securities began coverage on shares of Artivion (NYSE:AORT) in a note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $33.00 price target on the stock. JMP Securities’ price objective would indicate a potential upside of 23.97% from the company’s current price.

Other research analysts have also issued research reports about the stock. Stifel Nicolaus increased their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. Needham & Company LLC reissued a “buy” rating and set a $30.00 price target on shares of Artivion in a research report on Friday, September 27th. Oppenheimer lifted their price objective on Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, Lake Street Capital increased their target price on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $30.60.

Artivion Price Performance

Shares of NYSE AORT opened at $26.62 on Wednesday. The firm has a market cap of $1.11 billion, a P/E ratio of -110.92 and a beta of 1.74. The business’s 50 day moving average is $25.87 and its 200-day moving average is $24.61. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. Artivion has a 1-year low of $12.16 and a 1-year high of $29.24.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.04. The firm had revenue of $98.02 million for the quarter, compared to analysts’ expectations of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. Equities research analysts predict that Artivion will post 0.2 earnings per share for the current year.

Insiders Place Their Bets

In other news, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CAO Amy Horton sold 12,430 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the transaction, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at approximately $3,664,912.02. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Anthony B. Semedo sold 9,709 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total transaction of $242,627.91. Following the completion of the sale, the director now owns 34,159 shares in the company, valued at approximately $853,633.41. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,109 shares of company stock worth $951,935 over the last three months. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of AORT. Wasatch Advisors LP grew its position in Artivion by 108.8% during the 1st quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock worth $22,928,000 after acquiring an additional 564,549 shares during the last quarter. Perceptive Advisors LLC boosted its stake in shares of Artivion by 4.7% during the second quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock valued at $71,658,000 after purchasing an additional 124,725 shares in the last quarter. First Eagle Investment Management LLC grew its holdings in shares of Artivion by 8.1% during the first quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company’s stock worth $12,066,000 after purchasing an additional 42,705 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Artivion by 1.3% during the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock worth $56,388,000 after purchasing an additional 33,982 shares during the last quarter. Finally, Creative Planning increased its stake in shares of Artivion by 182.1% in the third quarter. Creative Planning now owns 28,635 shares of the company’s stock valued at $762,000 after buying an additional 18,486 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.